Merck сворачивает лекарство от гепатита С "Victrelis"
увидеть комментарии (0)
06.02.2015
Как отметили в компании, данное решение было принято на фоне выхода ряда новых лекарственных средств ("Sovaldi", "Harvoni" и "Viekira Pak") и, как следствие, снижения спроса на препарат. Однако, "Victrelis" будет доступен в США до конца 2015-го года, чтобы пациенты могли завершить 48-недельный курс лечения.
**************************
Merck & Co. said it will voluntarily discontinue manufacturing and distributing the hepatitis C therapy Victrelis (boceprevir) in the US by December this year. In a letter posted to the FDA's website, the company noted that the decision was based on "scientific advancement, changes in treatment practices, and the consequent reduction in the demand" for the product in the country.
Merck indicated that the therapy, which was approved by the FDA in 2011, will be supplied to wholesalers from existing inventories through the end of this year to ensure that patients currently using the drug will be able to complete up to 48 weeks of treatment. The drugmaker recommended that doctors do not start new patients on the treatment.
(Read full article at http://www.firstwordpharma.com/node/1258918#axzz3RAXaXEJ8 )
назад